Summary Keywords GLP 1, nausea & vomiting, obesity, semaglutide, side effect, tirzepatide Citation Alhazmi A and le Roux CW (2026) Do no harm: managing nausea and vomiting in GLP-1 based obesity therapies
doi: 10.1007/s11897-013-0133-0 20
RecoveryTissue-RepairInflammationMobilityInjuryRegenerationConnective-Tissue Acetyl Hexapeptide-8 peptide therapy supports skin smoothing and wrinkle reduction by relaxing facial tension
O'Hare HM, Duran R, Cervenansky C, Bellinzoni M, Wehenkel AM, Pritsch O, Obal G, Baumgartner J, Vialaret J, Johnsson K, Alzari PM: Regulation of glutamate metabolism by protein kinases in mycobacteria
Similar to Ipamorelin, GHRP-2, and GHRP-6 lead to an increase in appetite and weight gain Furthermore, GHRP-2 and GHRP-6 are not as selective as Ipamorelin
Reported tolerability in the available human observational work is high: no consistent pattern of adverse effects has been published, although the absence of placebo-controlled trials means subtle effects cannot be excluded